AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Gilead Sciences Stock Surges 87% in Volume, Ranks 52nd in Market Activity After FDA Approval of Twice-Yearly HIV Prevention Drug
Generated by AI AgentAinvest Volume Radar
Wednesday, Jun 18, 2025 8:10 pm ET1min read
On June 18, 2025,
(GILD) closed at a trading volume of $1.137 billion, marking an 87.25% increase from the previous day and ranking 52nd in the day's stock market activity. The company's stock price remained stable.Gilead Sciences received FDA approval for its twice-yearly injectable lenacapavir, marketed under the brand name Yeztugo, for HIV prevention. This approval marks the first time a twice-yearly PrEP option has been available, offering a significant convenience for patients. The medication has been shown to reduce the risk of HIV transmission by more than 99.9% in adults and adolescents.
This approval is a significant milestone for
, as it provides a new option for HIV prevention that requires only two treatments per year. The company has been working towards ending HIV, and this approval brings them one step closer to achieving that goal. The medication is now available in the United States for adults and adolescents weighing at least 35kg.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet